This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CalPERS Applauds CVS Caremark's Tobacco Exit

NEW YORK (TheStreet) - The California Public Employees Retirement System (CalPERS) said on Wednesday evening it applauded drugstore chain CVS Caremark's (CVS - Get Report) decision to end its sale of tobacco products in the company's 7,600 pharmacies nationwide by Oct. 1, 2014. The $277.2 billion pension is the nation's largest and has already taken a stand against big tobacco, divesting its passive investment in tobacco stocks in 2000.

"We applaud the decision by CVS to take this bold step and end its sale of tobacco products," CalPERS said in a statement. "The health of our members and their families is a top priority for our organization and clearly the use of tobacco is a key driver in the costs of health care. CVS' leadership helps promote a culture of wellness and health in our communities across the nation."

CalPERS is an important investor in CVS Caremark, and the first major fund to publicly support the company's landmark decision. The fund held about 3.38 million CVS Caremark shares as of the third-quarter of 2013, worth about $221 million according to Wednesday closing share prices.

CVS Caremark shares fell just over 1% on Wednesday after announcing its decision to stop selling tobacco products by the start of the third quarter of 2014.

Must Read: Surprise! The US is due for a recession in 2014

The move by CVS Caremark raises interesting questions about corporate governance and socially responsible investments that may gain further notice if other large CVS investors also take a stand.

Short-Term vs. Long-Term

CVS's decision could have a negative short-term impact on the company's earnings. However, the decision to end tobacco sales could also have a positive long-term impact on the company's positioning in the pharmacy business, especially as it works to expand its healthcare services in coming years.

TheStreet's Nicole Urken said in a Wednesday evening analysis that CVS's closer ties to healthy living categories could benefit long-term shareholders. Strong performing supermarkets and restaurants such as Whole Foods Market (WFM), Starbucks (SBUX) and Chipotle Mexican Grill (CMG) have all differentiated themselves with a focus on consumer health that's also translated into rising profitability.

It's also important to remember what CVS does.

CVS is one of the biggest pharmacy networks in the world and it's stores sell also drinks, snacks and other non-perishable foods that one might buy in a supermarket.

Nevertheless, the company's biggest recent investments are in healthcare. CVS acquired pharmacy-benefit-manager (PBM) Caremark in 2007, building a hybrid retail-PBM business model. Now, the company is investing heavily in a nationwide network of so-called MinuteClinics that may be a low-cost alternative to some doctor visits.

In that sense, CVS, above other competitors, appears to be the pharmacy chain with the biggest investment in healthcare. Thus, it also may have the greatest economic reason to end its sale of tobacco. Consumer perceptions are likely to be a big aspect of whether or not CVS can succeed in its healthcare investment.

CVS said its move would impact 2014 earnings guidance by 6-to-9 cents per share, but that the company "has identified incremental opportunities that are expected to offset the profitability impact." The company made no changes to its five-year financial projections.

From a short-term perspective, CVS's decision could lower the company's earnings by a few pennies. CVS said on Wednesday that ending tobacco sales may cause the company to lose $2 billion in annual revenue, or approximately 17 cents a share.

"Ending the sale of cigarettes and tobacco products at CVS/pharmacy is the right thing for us to do for our customers and our company to help people on their path to better health," Larry J. Merlo, CEO of CVS Caremark said in a statement. "Put simply, the sale of tobacco products is inconsistent with our purpose," he added.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CVS $104.21 0.28%
AAPL $95.01 -0.18%
FB $117.48 0.04%
GOOG $694.44 0.30%
TSLA $231.92 -0.17%


Chart of I:DJI
DOW 17,724.51 -26.40 -0.15%
S&P 500 2,056.47 -6.90 -0.33%
NASDAQ 4,749.7220 -13.5020 -0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs